Kornimate/medical-research-clean huggingface dataset:
the effect of facial effleurage on acute rhinosinusitis

Conditions: Rhinosinusitis Acute

Summary: rhinosinusitis accounts for 12% of the total antibiotic prescriptions filled in the united states annually; however, the majority of rhinosinusitis cases have been proposed to have a viral etiology, or are capable of spontaneously resolving. this overuse of antibiotics is contributing to the development of antibiotic-resistant human pathogenic bacteria, and increasing patient mortality to previously easily cured diseases. this is also causing an unnecessary financial burden especially for uninsured, rural families. facial effleurage (fe) is an osteopathic manipulative therapy that allows physicians an alternative therapy to prescribing antibiotics; however, the only scientific literature on the technique is weak in design and execution. this will be a randomized, placebo-controlled clinical trial to test the ability of fe to reduce symptom severity over time, reduce the cellular infiltrate into the nasal cavity, and to more quickly resolve the symptoms of rhinosinusitis compared to antibiotic treatment. this methodical approach to the efficacy of fe has the potential to impact the treatment recommendations of physicians immediately, and to convince more physicians to prescribe less antibiotics and rely more heavily on fe.


Eligibility criteria:
inclusion criteria: * presents with no acute disease or * presents with anterior/posterior mucopurulent drainage and nasal obstruction/facial pain/pressure/fullness * independently and without coercion read, understood, and signed the informed consent form * is between 18-69 years old. exclusion criteria: * history of: cancer, hiv, hiv exposure, osteoporosis, acute hepatitis, cystic fibrosis, type-1 diabetes, taking insulin for diabetes, deep vein thrombosis, pulmonary embolism * history of recent trauma to the liver or spleen or surgery within the past 6 months * currently pregnant or nursing * have a comorbidity that requires antibiotics or antiviral therapy * have a fever greater than 102.5f * used topical antimicrobials in the past 30 days * taken oral antimicrobials in the past 15 days * participated in a clinical trial in the past 6 months * have current face or neck bone fractures * have abscesses, incisions, or nasal polyps visible on physical examination * need to be hospitalized for any reason

Keywords: osteopathic manipulative treatment
study of external beam radiotherapy to thyroid carcinoma

Conditions: Thyroid Cancer

Summary: the primary objective of this study is to estimate the 5 year locoregional control rate after external beam radiotherapy (ebrt) in the patient with locally advanced differentiated thyroid cancer. in a prior retrospective trial for this same group of patients, the 5 year locoregional control rate was 85% in ebrt group and 70% in no ebrt group. for the total number of patients to detect a minimum of 20% improvement in 5 year locoregional control rate with 80% of statistical power and the 5% significance level, the table for sample size planning given by makuch and simon was chosen. forty-three patients are required for this regimen to regard as worthy of further investigation. considering 15% follow up loss, 50 eligible patients will be enrolled.

the standard approaches to the treatment of differentiated thyroid cancer include surgical resection, radioactive iodine treatment, and thyroid-stimulating hormone suppression. the role of external beam radiotherapy (ebrt), however, remains controversial. the purpose of this phase ii study is to evaluate the impact of ebrt on the locoregional control in locoregionally advanced or recurrent differentiated thyroid cancer patients.

Eligibility criteria:
inclusion criteria: * pathologically confirmed differentiated thyroid cancer * patient with locally advanced tumor (t4a, tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve or t4b, tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels or n1b, unilateral, bilateral, or contralateral cervical or mediastinal lymph node positive), or locoregionally recurrent tumor * all patients must have radiographically assessable disease * no previous irradiation to the planned field * age of ≥ 18 years * performance status of 0 to 2 on the eastern cooperative oncology group (ecog) score * required entry laboratory parameters wbc count ≥ 1,000/mm3; hemoglobin level ≥ 7.5 g/dl; platelet count ≥ 100,000/mm3; creatinine ≤ 3.0 mg/dl * oral intake (including j-tube feeding) of ≥ 1,500 calories/day should be maintained. * signed informed consent form prior to study entry exclusion criteria: * patient with anaplastic carcinoma (focal anaplastic change associate with differentiated thyroid cancer is not excluded) * age of \<18 years * previous history of rt adjacent to planned field * poor performance status of 3 to 4 on the eastern cooperative oncology group (ecog) score * pregnant or breast feeding status * previous history of uncontrolled other malignancies within 2 years

Keywords: thyroid carcinoma external beam radiotherapy
phase iii study of an otic formulation in acute otitis media with tympanostomy tubes

Conditions: Acute Otitis Media

Summary: the purpose of this study is to determine if a topical otic formulation is safe and effective in treating middle ear infections in patients with ear tubes.


Eligibility criteria:
inclusion criteria: * 6 months to 12 years old * ear tubes in one or both ears * ear drainage visible by the parent / guardian * ear drainage less than 21 days * ear tube may not be silver oxide, silver salt, t-type tube or long-shafted tube * patient may not have non-tube otorrhea * patient may not have had otic surgery other than tube placement in the last year * patient may not be a menarchal female * diabetic patients are not eligible * patient may not have any disease or condition that would negatively affect the conduct of the study * patient may not require any other systemic antimicrobial therapy during the study. * patient must meet certain medication washouts to be eligible * analgesic use (other than acetaminophen) is not allowed * patient may not be pre-disposed to neurosensory hearing loss * other protocol-defined inclusion criteria may apply exclusion criteria: * age * other protocol-defined exclusion criteria may apply

Keywords: ear tubes ear drainage ear infection ear drops
study of early stage endometrial cancer based on molecular classification and traditional risk stratification to guide adjuvant radiotherapy decisions

Conditions: Endometrial Cancer; Adjuvant Radiotherapy; Molecular Classification

Summary: the purpose of this study is to compare the efficacy and toxicity of early stage endometrial cancer based on molecular classification and conventional risk stratification adjuvant therapy decision-making, and to provide high-quality evidence-based medical evidence for individualized adjuvant therapy selection under the guidance of fine stratification system of endometrial cancer.

this is an investigator-initiated prospective, national multicentre, phase iii, randomised, open, non-inferiority clinical study. the study hypothesis is that adjuvant radiotherapy decision for early-stage endometrial cancer which is based on molecular classification can achieve de-escalation of adjuvant treatment without reducing local tumour control and survival, thereby potentially further reducing radiotherapy-related toxicity and improving quality of life, compared to using conventional risk stratification. the primary endpoint of this study is the 3-year local recurrence rate.

Eligibility criteria:
inclusion criteria: 1. women aged 18-75. 2. patients with newly histologically confirmed endometrioid adenocarcinoma. 3. ecog score 0-2 4. surgery consisting of a total hysterectomy and bilateral salpingo-oophorectomy, pelvic lymphadenectomy or sentinel lymph node biopsy, with or without para-aortic lymphadenectomy, oophorectomy 5. patients with figo staging(2009 edition) i or ii and meet one of the following conditions: 1. stage ia g1-2 with massive lvsi+ or age ≥ 60 years 2. stage ia g3, regardless of lvsi status 3. stage ib g1-3, regardless of lvsi status 4. stage ii, regardless of tumor grade and lvsi status 6. patients can understand the study protocol and voluntarily participate in the study, and give written informed consent before treatment. exclusion criteria: 1. not figo stage i-ii. 2. residual tumor or positive margin. 3. mixed carcinoma, sarcoma or carcinosarcoma 4. previous history of malignant tumor 5. previous history of pelvic radiotherapy 6. the interval between surgery and radiotherapy is more than 12 weeks. 7. with serious medical complications, such as heart disease, lung disease and other diseases that cannot tolerate the whole course of radiotherapy

Keywords: endometrial cancer
psilocybin for the treatment of migraine headache

Conditions: Migraine Headache

Summary: the purpose of this study is to investigate the effects of oral psilocybin in migraine headache. subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart. subjects will be randomized to the order of treatment and they will be randomized to receive either low or high dose psilocybin. subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. this preliminary study will inform on the basic effects of psilocybin in migraine headache and inform on the design of larger, more definitive studies.

the number of arms reflects the design of the enhanced blinding method. the final enrollment number reflects the number of subjects participating in study procedures.

Eligibility criteria:
inclusion criteria: * diagnosis of migraine headache per ichd-3beta criteria * typical pattern of migraine attacks with approximately two migraines or more weekly * attacks are managed by means involving no more than twice weekly triptan use * age 21 to 65 exclusion criteria: * axis i psychotic disorder (e.g. schizophrenia, bipolar i, depression with psychosis) * axis i psychotic disorder in first degree relative * unstable medical condition, severe renal, cardiac or hepatic disease, pacemaker, or serious central nervous system pathology * pregnant, breastfeeding, lack of adequate birth control * history of intolerance to psilocybin, lsd, or related compounds * drug or alcohol abuse within the past 3 months (excluding tobacco) * urine toxicology positive to drugs of abuse * use of vasoconstrictive medications (i.e. sumatriptan, pseudoephedrine, midodrine) within 5 half-lives of test days * use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks * use of antidepressant medication (i.e. tca, maoi, ssri) in the past 6 weeks * use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks

Keywords: psilocybin
a long term study to evaluate the safety, tolerability and efficacy of cp-690,550 in patients with moderate to severe plaque psoriasis and/or psoriatic arthritis

Conditions: Psoriasis

Summary: the main objective of this study is to evaluate the long term safety of cp-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. this study will also to compare the efficacy of two oral doses of cp-690,550 (5 mg bid and 10 mg bid) after 16 weeks of treatment.


Eligibility criteria:
inclusion criteria: * are 20 years or older and considered to be candidates for systemic or phototherapy. \[moderate to severe plaque psoriasis\] * diagnosed for at least 12 months. * have psoriasis area and severity index (pasi) score of 12 and plaque type psoriasis covering at least 10% of body surface area (bsa). \[psoriatic arthritis\] * diagnosed for at least 6 months. * meet the caspar (classification criteria for psoriatic arthritis) criteria at screening; * have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and active plaque psoriasis with at least 2 cm in diameter. exclusion criteria: * non-plaque or drug induced forms of psoriasis * cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic arthritis or cannot discontinue phototherapy (puva or uvb) * any uncontrolled significant medical condition

Keywords: chronic severe moderate treatment safety efficacy cp-690 550 plaque psoriasis psoriasis vulgaris psoriatic arthritis tofacitinib xeljanz
minimizing ventricular pacing

Conditions: Sinus Node Disease.; First Degree Atrioventricular Block.

Summary: the aim of this study is to evaluate the effect of minimizing right ventricular pacing in dual-chamber pacemaker patients with sinus node disease (snd) and first degree atrioventricular block (avib)on exercise capacity, quality of life and other heart failure measures.


Eligibility criteria:
inclusion criteria: * prolonged pq interval \> 200 ms, * percentage of right ventricular pacing with standard av delay \> 90. exclusion criteria: * second or third degree atrioventricular block, * permanent atrial fibrillation.
evaluation of the care path of patients who have been sexually assaulted

Conditions: Sexually Transmitted Diseases

Summary: the main objective of this study is to describe the care pathway of patients presenting in the medico-judicial unit of the raymond poincaré hospital in garches, france, following a complaint for sexual assault and suggest ways to improvement of the care adapted to the characteristics of the participants.

as secondary objectives, the study aims to: * analyze the population of victims of sexual assault seen in consultation at the medico-judicial unit of raymond poincaré hospital. * analyze the decision elements of the initiation of the post-exposure treatment and evaluate them against the recommendations. * analyze the data collected on the patients and their follow-up in consultation of infectious disease of the hospital of garches following a sexual assault. * identify obstacles encountered by participants to follow the complete follow-up path. for this purpose the data collection will be done initially within the forensic unit of raymond poincaré hospital. then, in a second step, the patients requiring the setting up of a post-exposure treatment, are addressed in the service of infectious diseases. the compilations of the data necessary for the study will then be continued until 3 months after the sexual assault. for the collection of data, they will be based on the medical records of the victims.

Eligibility criteria:
inclusion criteria: * people declared being victim of sexual assault; * consult at medical-legal unit; * judicial requirement. exclusion criteria: - absence of judicial requirement.

Keywords: sex offenses sexually transmitted diseases traumatic injury
a clinical trial of the optimal treatment period and long-term efficacy of functional electrical stimulation (fes) on sleep bruxism

Conditions: Temporomandibular Disorder; Headache

Summary: to investigate the effect of the treatment with grindcare® on the parafunction of the muscles- and jaw activity (bruxism) during sleep.


Eligibility criteria:
inclusion criteria: * rdc-tmd diagnosis * verified sleep bruxism * more than 18 years * signed icf exclusion criteria: * contraindication of concomitant medication and diseases judged by investigator * pacemaker
neoadjuvant treatment of upper urinary and muscular invasive bladder urothelial carcinoma

Conditions: Upper Tract Urinary Carcinoma; Muscle-invasive Bladder Cancer

Summary: few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant treatment model might benefit patients. so this prospective phase ii clinical trial was designed to explore the efficacy of chemotherapy combined with pd-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive bladder urothelial carcinoma, then to improve the rate of complete pathological remission, survival and provide medical evidence.


Eligibility criteria:
inclusion criteria: 1. bladder cancer of t2-4an0m0 2. upper tract urinary carcinoma of t1-3n0m0 and high grade 3. ecog 0-1 4. good organ function 5. no previous chemotherapy or immunotherapy 6. informed consent form signed exclusion criteria: 1. unable to receive chemotherapy or surgery due to physical abnormalities 2. previous cancer history 3. active tuberculosis 4. hiv 5. autoimmune disease 6. anticipating other clinical studies

Keywords: upper tract urinary carcinoma muscle-invasive bladder cancer neoadjuvant chemotherapy immunotherapy
an assessment of intra-lesional 3% polidocanol solution in the treatment of digital myxoid cyst

Conditions: Ganglion Cysts

Summary: digital myxoid cysts arise from degeneration in the connective tissue of the digit joint, usually the last joint of the finger or toe, often due to underlying joint arthritis. they may connect with the joint. pressure from the cyst can result in deformity of the digit's nail and trauma to the cyst results in leakage of the fluid, representing a potential source of entry for infection. cysts can be tender and interfere with the digit's function. a variety of treatments are available, from simple extrusion which is rarely successful, to more destructive cryotherapy, infra-red coagulation and formal excision under local anaesthetic. these latter three approaches can result in considerable scarring. sclerosant injection of polidocanol in one small non-randomised trial has been reported to be a well tolerated efficacious treatment with minimal scarring and long-term resolution. following a pilot study, the investigators aim to trial this treatment to assess efficacy in a larger population.


Eligibility criteria:
inclusion criteria: * all patients referred to dermatology in nhs lothian or nhs fife who have a visible digital myxoid cyst affective the dital phalynx of the toes or fingers. * the patient must have the ability to give informed consent exclusion criteria: * history of sensitivity to polidocanol or other sclerosants * age less than 18 * inability to give informed consent * inability to report side effects experienced * cyst not clearly visible * cyst not fluid-filled
sense2stop:mobile sensor data to knowledge

Conditions: Stress; Smoking Cessation; Overeating

Summary: the aim of this research is to build systems that can recognize when people are stressed and then provide them with relaxation prompts in the moment to reduce their likelihood of being stressed, smoking, or overeating in the near future. using these systems should help smokers be more effective in their attempts to quit by reducing their tendency to lapse when they are stressed or experiencing other negative moods or behaviors.

the purpose of this study is (1) to evaluate the feasibility of a just-in-time intervention to decrease stress in recently quit smokers; and (2) to examine whether a just-in-time adaptive intervention that decreases stress also reduces the near-term odds of a smoking lapse. the primary hypothesis of this study is that the administration of a prompt to perform a relaxation exercise as compared to no prompt will lead to a lower likelihood of being stressed in the subsequent two hours, and that this effect will be stronger when the prompt is administered when the individual is stressed. the secondary hypothesis is that stress episodes will predict the timing of smoking lapses. the third hypothesis is that administration of a prompt to perform a relaxation exercise will reduce the odds of smoking for the next two hours, and that this effect will be stronger when the prompt is administered when the individual is stressed. the fourth (exploratory) hypothesis is that stress will predict the timing of overeating episodes. these data will also be used for developing automated risk prediction of smoking relapse, and for developing decision rules for the timing of just-in-time-adaptive interventions (jitais).

Eligibility criteria:
inclusion criteria: * smokes 1+ cigarettes/day for past year * willing to try to quit smoking for at least 48 hours during a 15-day quit trial * will not use non-cigarette tobacco products or nicotine replacement therapy during the study period * not taking or intending to take pharmacological smoking cessation aids (e.g., nicotine replacement, bupropion, venlafaxene) during the study period exclusion criteria: * unable to wear study devices due to skin irritation or sizing limitations * planning to move outside of chicago area during study period * adults unable to provide informed consent * individuals who are not yet adults * pregnant women * prisoners * non-english speakers

Keywords: behavioral counseling cigarette smoking mobile health heart rate variability monitoring mindfulness-based exercises mobile apps physiological monitoring respiratory pattern monitoring stress-management interventions sensor-triggered stress intervention smartphone apps smoking cessation wearable sensors eating behavior stress-related eating
ranibizumab for myopic neovascularization

Conditions: Myopic Choroidal Neovascularization

Summary: the purpose of this study is to evaluate the clinical results of anti-vegf intra-vitreal injections (ivt) in cnv secondary to pathologic myopia (pm-cnv).

twenty consecutive patients (30 eyes) with subfoveal pm-cnv, 9 of whom had been unsuccessfully treated with visudyne pdt, were treated with ivt of 0.5mg ranibizumab. etdrs best corrected visual acuity, macular thickness on oct scans, and angiographic features were recorded and evaluated. the aspect of oct scans passing across the pm-cnv was also analyzed. ivts were repeated only in case of persistent angiographic leakage and if oct scans showed retinal thickening or edema and serous retinal detachment. the follow-up period was at least 6 months.

Eligibility criteria:
inclusion criteria: * myopic and cnvm exclusion criteria: * patients with poor compliance * patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of stroke or myocardial infraction (\< one year). (physician clearance was obtained for all patients). * age related macular degeneration with juxtafoveal and subfoveal cnvm: recurrent cnvm following pdt and ttt with ivta. patient who could not afford pdt, macugen or lucentis which is fda approved. * patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery. * refractory macular oedema due to vein occlusion, pseudophakia, clinically significant macular oedema (csme) etc. that affects vision and does not respond adequately to usual treatment methods. * proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with pdr. * idiopathic cnvm, inflammatory cnvm and other conditions associated with cnvm.

Keywords: ranibizumab myopia complications neovascularization oct